Evidence map›Paper›PMID 28515303›Full record

ArticleJournal of virology2017

Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.

Rosie T Jiang, Joshua W Wang, Shiwen Peng, Tsui-Chin Huang, Chenguang Wang, Fabiana Cannella, Yung-Nien Chang, Raphael P Viscidi, Simon R A Best, Chien-Fu Hung and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. First Report ofViruses · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. A NovelmBio · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Rosie T JiangDepartment of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA.
Joshua W WangDepartment of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA.
Shiwen PengDepartment of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA.
Tsui-Chin HuangGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, Republic of China.
Chenguang WangDepartment of Oncology, The Johns Hopkins University, Baltimore, Maryland, USA.
Fabiana CannellaIstituto Pasteur Italia-Cenci Bolognetti Foundation, Sapienza University, Rome, Italy.
Yung-Nien ChangDepartment of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA.
Raphael P ViscidiDepartment of Pediatrics, The Johns Hopkins University, Baltimore, Maryland, USA.
Simon R A BestDepartment of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University, Baltimore, Maryland, USA.
Chien-Fu HungDepartment of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA.
Richard B S RodenDepartment of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA roden@jhmi.edu.ORCID http://orcid.org/0000-0002-2506-0195
Johns Hopkins University · USIstituto Pasteur · ITTaipei Medical University · TW

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZYY-CHOOU WU · 2003 to 2026
$53.5M
Mechanisms of Papillomavirus NeutralizationR01CA118790 · NCI · JOHNS HOPKINS UNIVERSITY · PI RODEN, RICHARD BRUCE · 2007 to 2018
$2.9M
Therapeutic/preventive vaccination against MusPVR43AI112421 · NIAID · PAPIVAX, LLC · PI CHANG, YUNG-NIEN · 2014 to 2015
$595k
Molecular pathogenesis and host response following persistent E6/E7 expressionR21AI109259 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2014 to 2015
$446k
NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA118790NIAID NIH HHS R21 AI109259NIAID NIH HHS R43 AI112421
6 · The paper itself

Abstract

Mus musculus papillomavirus 1 (MmuPV1/MusPV1) induces persistent papillomas in immunodeficient mice but not in common laboratory strains. To facilitate the study of immune control, we sought an outbred and immunocompetent laboratory mouse strain in which persistent papillomas could be established. We found that challenge of SKH1 mice (Crl:SKH1-Hrhr) with MmuPV1 by scarification on their tail resulted in three clinical outcomes: (i) persistent (>2-month) papillomas (∼20%); (ii) transient papillomas that spontaneously regress, typically within 2 months (∼15%); and (iii) no visible papillomas and viral clearance (∼65%). SKH1 mice with persistent papillomas were treated by using a candidate preventive/therapeutic naked-DNA vaccine that expresses human calreticulin (hCRT) fused in frame to MmuPV1 E6 (mE6) and mE7 early proteins and residues 11 to 200 of the late protein L2 (hCRTmE6/mE7/mL2). Three intramuscular DNA vaccinations were delivered biweekly via

Indexed as

Disease Models, AnimalAnimalsAntibodies, ViralCD8-Positive T-LymphocytesInjections, IntramuscularMicePapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesTreatment OutcomeVaccines, DNAAntibodies, ViralPapillomavirus VaccinesVaccines, DNADNA vaccinesmouse modelneutralizing antibodiespapillomavirusSKH-1 miceT cells

Identifiers

PMID28515303
PMCPMC5512245
OpenAlexW2616449719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.